BIIB Related StreetInsider.com Reports
-
Vivus (VVUS) Sees Upside on Icahn Connection
-
Biogen Idec (BIIB) Appoints Spyros Artavanis-Tsakonas as CSO
-
Biogen's (BIIB) BG-12 Data Not Inflated
-
Biogen (BIIB) Weeks-6 TECFIDERA Scripts Continue to Ramp
-
Biogen's (BIIB) TECFIDERA Scripts Accelerating WoW
-
StreetInsider.com Pre-Open Movers 5/13: (THRX) (MTSN) (TSLA) Higher; (AFFY) (CEL) (UNXL) Lower (more...)
-
Biogen (BIIB) BLA for ELOCTATE Accepted by FDA
-
Scripts Data Indicates Biogen's (BIIB) Tecfidera Could Beat 2013 Estimates by $400M
-
StreetInsider.com Pre-Open Movers 5/1: (IQNT) (MSPD) (RATE) Higher; (HIMX) (MELA) (MRK) Lower (more...)
-
Goldman Sachs Downgrades Biogen (BIIB) to Neutral, Removes from CL List
-
Goldman Sachs Upgrades Amgen (AMGN) to Conviction Buy
-
Deutsche Bank Sees Upside for Biogen's (BIIB) Tecfidera
-
Biogen Idec (BIIB) Pops on Strong Tecfidera Rx Growth
-
Jefferies Lifts Numbers on Biogen (BIIB) Post Q1
-
Deutsche Bank Maintains Buy on Biogen (BIIB)
-
StreetInsider.com Pre-Open Movers 4/25: (AKAM) (INFN) (FIO) Higher; (XIDE) (INTU) (CTXS) Lower (more...)
-
Biogen Idec, Inc. (BIIB) Tops Q1 EPS by 34c; Boosts FY13 Outlook
-
Trading Radar for 04/25: Exxon, (XOM), Dow (DOW), 3M (MMM), Hershey (HSY), UPS (UPS), Expedia (EXPE) Report
-
Deutsche Bank Raises Biogen (BIIB) Price Target to $240
-
Notable 52-Week Highs and Lows of the Day 04/22: (HAS) (CELG) (RAD) High; (MHR) (BTU) Low
-
Strong Biogen (BIIB) Tecfideara Sales Tied to Patient 'Warehousing'
-
Early Data Says Biogen's (BIIB) Tecfidera Doing Well - Analyst
-
UPDATE: Glaxo (GSK) wins appeals court ruling over Biogen Idec (BIIB) cancer patent
-
BofA/Merrill Lynch Upgrades Biogen (BIIB) to Buy
-
RBC Capital Raises PT on Biogen (BIIB) to $215
-
Top 10 News Items for 03/25 - 03/28: S&P 500 Hits New Record High; Q4 U.S. GDP Growth Ebbs; Investors Flock Dell
-
Notable 52-Week Highs and Lows of the Day 03/28: (GILD) (GME) (BIIB) High; (SXE) (TXCC) Low
-
StreetInsider.com Pre-Open Movers 03/28: (RPRX) (DECK) (XONE) Higher; (FIVE) (RHT) (GME) Lower (more...)
-
Biogen (BIIB) Target Raised to $215 at Jefferies after Tecfidera Approved with Favorable Label
-
JMP Securities Starts Biogen (BIIB) at Market Outperform
-
What Next for Biogen (BIIB)? Anlaysts Weigh In
-
Market Wrap: Biogen's MS Treatment OK'd; Cyprus Plans to Open Banks; F-35 Financing Approved
-
Biogen Idec (BIIB) Affirms Receipt of FDA Approval for TECFIDERA as MS Treatment
-
XenoPort (XNPT) Pops Higher on Biogen (BIIB) Tecfidera Approval
-
Teva (TEVA) Hits Session Lows as Biogen (BIIB) MS Pill Gains Approval
-
UPDATE: Biogen Idec (BIIB) wins FDA approval for MS pill
-
Jefferies Maintains Bullish Stance on Biogen (BIIB) after AAN Meeting
-
Biogen Idec (BIIB) TECFIDERA Receives Positive EMA CHMP Opinion
-
Biogen Idec (BIIB) TECFIDERA gets positive opinion from EMA.
-
Biogen Idec (BIIB) PLEGRIDY Met Primary Endpoint in Phase 3 ADVANCE
-
Biogen Idec (BIIB), Elan (ELN) to Present Positive Data for Tysabri on MS Supporting JCV
-
Biogen Idec (BIIB) Submits BLA to FDA for rFVIIIFc as Hemophilia A Treatment
-
Elan Corp. (ELN) Sees Tysabri Closing Within Weeks; Approves $1B Buyback
-
Biogen Idec (BIIB) BLA for rFIXFc Accepted by FDA
-
Elan Corp (ELN) Initiates New Dividend Program; Will Be Tied to Tysabri Performance
-
UPDATE: Bristol-Myers (BMY) Considered Deals for Biogen (BIIB), Shire (SHPG) - DJN
-
Canaccord Genuity Upgrades Biogen (BIIB) to Buy
-
Citi Upgrades Biogen (BIIB) to Buy
-
Market Wrap: Liberty Makes Virgin Deal Official; New Schedule for USPS; Barclays to Trim NY Jobs
-
Deutsche Bank Boosts PT on Biogen (BIIB) to $170 on Tysabri Deal
Back to BIIB Stock Lookup
